WEKO3
アイテム
Therapeutic efficacy of α-emitter meta-211At-astato-benzylguanidine (MABG) in a pheochromocytoma model
https://repo.qst.go.jp/records/66693
https://repo.qst.go.jp/records/66693f79e9cb6-7c7f-4d69-bb99-cbfd6c3b01d2
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2018-03-26 | |||||
| タイトル | ||||||
| タイトル | Therapeutic efficacy of α-emitter meta-211At-astato-benzylguanidine (MABG) in a pheochromocytoma model | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
大島, 康宏
× 大島, 康宏× 渡辺, 茂樹× 辻, 厚至× 永津, 弘太郎× 坂下, 哲哉× 杉山, 僚× 原田, 良信× 脇, 厚生× 吉永, 恵一郎× 東, 達也× 石岡, 典子× 大島 康宏× 渡辺 茂樹× 辻 厚至× 永津 弘太郎× 坂下 哲哉× 杉山 僚× 原田 良信× 脇 厚生× 吉永 恵一郎× 東 達也× 石岡 典子 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Beta-emitting meta-131I-iodo-benzylguanidine (MIBG) has been used in the treatment of malignant pheochromocytoma (PHEO). However the effects of MIBG and 5-year survival are limited. Alpha-emitters strongly suppress the growth of tumor cells. 211Astatine (211At) is an α-emitting halogen and has a suitable half-life for cancer therapy (t1/2=7.2 h). Therefore, meta-211At-astatobenzylguanidine (MABG) may potentially suppress the growth of malignant PHEO. In this study, we synthesized MABG and investigate the therapeutic effects of MABG in a rat PHEO model. 211At was produced via the 209Bi(α,2n)211At reaction and was isolated through dry distillation. MABG was synthesized by astatination of meta-trimethylsilylbenzylguanidine hemisulfate. MABG was highly taken up into a rat PHEO cell line, PC-12, through the norepinephrine transporter, and significantly suppressed clonogenic growth. DNA damage and cell cycle arrest at the G2/M phase were observed after MABG treatment. Biodistribution and therapeutic effects were examined using mice bearing PC-12. MABG was highly distributed and was retained in tumors. Furthermore, the tumor size was significantly reduced by the single administration of MABG (555 kBq/head) without an associated weight reduction. These results suggest that MABG might be an attractive therapeutic agent for the treatment of malignant PHEO. | |||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Society of Nuclear Medicine and Molecular Imaging 2016 Annual Meeting | |||||
| 発表年月日 | ||||||
| 日付 | 2016-06-14 | |||||
| 日付タイプ | Issued | |||||
